Incidence of Active Tuberculosis in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
Kohei Fujita, Yuki Yamamoto, Osamu Kanai, Misato Okamura, Masayuki Hashimoto, Koichi Nakatani, Satoru Sawai, Tadashi Mio
Abstract
Although it ameliorates lung cancer, immunotherapy with immune checkpoint inhibitors (ICIs) presents complications of infectious diseases, including tuberculosis. Incidence of tuberculosis during immunotherapy remains unclear. We found that 1.7% of patients developed active tuberculosis during immunotherapy at our institution. In patients with a positive interferon-gamma release assay status before ICI therapy, physicians should pay close attention to developing tuberculosis.
Topics & Concepts
MedicineTuberculosisImmunotherapyLung cancerIncidence (geometry)ImmunologyInternal medicineActive tuberculosisImmune systemOncologyMycobacterium tuberculosisPathologyPhysicsOpticsTuberculosis Research and EpidemiologyCancer Immunotherapy and BiomarkersMycobacterium research and diagnosis